Evidence map›Paper›PMID 28228842›Full record

ArticleInfectious agents and cancer2017

Worldwide malaria incidence and cancer mortality are inversely associated.

Li Qin, Changzhong Chen, Lili Chen, Ran Xue, Ming Ou-Yang, Chengzhi Zhou, Siting Zhao, Zhengxiang He, Yu Xia, Jianxing He and 3 more

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Infectious agents and cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
7.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03375983 phase1 / phase2unknown statusnot on this map

Clinical Study of Plasmodium Immunotherapy for Advanced Cancers

TypeinterventionalSponsorCAS Lamvac Biotech Co., Ltd.Ran2017 to 2026Enrolled20ConditionsAdvanced CancersArmsBlood-stage infection of P.vivax
NCT03474822 phase1 / phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Clinical Study of Plasmodium Immunotherapy for Advanced Breast Cancers and Advanced Liver Cancers

TypeinterventionalSponsorCAS Lamvac Biotech Co., Ltd.Ran2018 to 2026Enrolled60ConditionsAdvanced Breast Cancer, Advanced Liver CancerArmsBlood-stage infection of P.vivax
NCT04165590 phase1 / phase2recruitingnot on this mapstarted 2019, after this paper: background citation

Clinical Study of Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

TypeinterventionalSponsorCAS Lamvac Biotech Co., Ltd.Ran2019 to 2026Enrolled60ConditionsAdvanced Malignant Solid TumorArmsPlasmodium immunotherapy
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Bugs as drugs: parasite biomolecules as novel therapeutics against breast cancer.American journal of physiology. Cell physiology · 2026
    Review
  4. The theory of tumor immuno-ecodynamics.Frontiers in immunology · 2026
    Article
  5. Article
  6. Review
  7. Oncology letters · 2024
    Article
  8. Parasites revive hope for cancer therapy.European journal of medical research · 2024
    Review
  9. Review
  10. Review
  11. Molecular Research on Plasmodium Infection and Immunity.International journal of molecular sciences · 2024
    Article
  12. Article
  13. Parasites as potential targets for cancer immunotherapy.Journal of cancer research and clinical oncology · 2023
    Review
  14. Frontiers in oncology · 2023
    Article
  15. A novel enemy of cancer: recent investigations into protozoan anti-tumor properties.Frontiers in cellular and infection microbiology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. The mechanisms of action of Plasmodium infection against cancer.Cell communication and signaling : CCS · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Li Qin *State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, 510530 Guangzhou, China.
Changzhong Chen *Channing Laboratory, Brigham and Women's Hospital, 181 Longwood Ave, Boston, MA 02115 USA.
Lili ChenState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, 510530 Guangzhou, China.
Ran XueBoston University, Boston, MA 02215 USA.
Ming Ou-YangState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital, Guangzhou Medical University, 151 Yanjiang Road, 510120 Guangzhou, China.
Chengzhi ZhouState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital, Guangzhou Medical University, 151 Yanjiang Road, 510120 Guangzhou, China.
Siting ZhaoState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, 510530 Guangzhou, China.
Zhengxiang HeState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, 510530 Guangzhou, China.
Yu XiaDepartment of Bioengineering, McGill University, Montreal, QC H3A 0C3 Canada.
Jianxing HeState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital, Guangzhou Medical University, 151 Yanjiang Road, 510120 Guangzhou, China.
Pinghua LiuBoston University, Boston, MA 02215 USA.
Nanshan ZhongState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital, Guangzhou Medical University, 151 Yanjiang Road, 510120 Guangzhou, China.
Xiaoping ChenState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, 510530 Guangzhou, China.
State Key Laboratory of Respiratory Disease · CNGuangzhou Medical University · CNBoston University · USGuangzhou Institutes of Biomedicine and Health · CNBrigham and Women's Hospital · USMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvestigations on the effects of malaria infection on cancer mortality are limited except for the incidence of Burkitt's lymphoma (BL) in African children. Our previous murine lung cancer model study demonstrated that malaria infection significantly inhibited tumor growth and prolonged the life span of tumor-bearing mice. This study aims to assess the possible associations between malaria incidence and human cancer mortality.

methodsWe compiled data on worldwide malaria incidence and age-standardized mortality related to 30 types of cancer in 56 countries for the period 1955-2008, and analyzed their longitudinal correlations by a generalized additive mixed model (GAMM), adjusted for a nonlinear year effect and potential confounders such as country's income levels, life expectancies and geographical locations.

resultsMalaria incidence was negatively correlated with all-cause cancer mortality, yielding regression coefficients (log scale) of -0.020 (95%CI: -0.027,-0.014) for men (

conclusionsOur analysis revealed a possible inverse association between malaria incidence and the mortalities of all-cause and some types of solid cancers, which is opposite to the known effect of malaria on the pathogenesis of Burkitt's lymphoma. Activation of the whole immune system, inhibition of tumor angiogenesis by

Indexed as

Cancer mortalityEpidemiological dataGeneralized additive mixed model (GAMM)Malaria incidenceRegression analysis

Identifiers

PMID28228842
PMCPMC5307699
OpenAlexW2589085056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.